Filtered By:
Drug: SGLT2 Inhibitors
This page shows you your search results in order of relevance. This is page number 10.
Order by Relevance | Date
Total 230 results found since Jan 2013.
Effects of Sodium-Glucose Transporter 2 Inhibitors (SGLT2-I) in Patients With Ischemic Heart Disease (IHD) Treated by Coronary Artery Bypass Grafting via MiECC: Inflammatory Burden, and Clinical Outcomes at 5 Years of Follow-Up
Conclusion: In T2DM patients, the SGLT2-I significantly reduced the inflammatory burden and ameliorated clinical outcomes at 5 years of follow-up post-CABG via MiECC.
Source: Frontiers in Pharmacology - November 15, 2021 Category: Drugs & Pharmacology Source Type: research
Correction to: The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus
Source: Cardiovascular Drugs and Therapy - December 24, 2021 Category: Cardiology Source Type: research
Sodium-Glucose Cotransporter-2 Inhibitors in Vascular Biology: Cellular and Molecular Mechanisms
AbstractSodium-glucose cotransporter-2 (SGLT2) inhibitors are new antidiabetic drugs that reduce hyperglycemia by inhibiting the glucose reabsorption in renal proximal tubules. Clinical studies have shown that SGLT2 inhibitors not only improve glycemic control but also reduce major adverse cardiovascular events (MACE, cardiovascular and total mortality, fatal or nonfatal myocardial infarction or stroke) and hospitalization for heart failure (HF), and improve outcome in chronic kidney disease. These cardiovascular and renal benefits have now been confirmed in both diabetes and non-diabetes patients. The precise mechanism(s)...
Source: Cardiovascular Drugs and Therapy - December 1, 2021 Category: Cardiology Source Type: research
Response to the Letter on “The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus”
Source: Cardiovascular Drugs and Therapy - January 10, 2022 Category: Cardiology Source Type: research
Determining the role of SGLT2 inhibition with Empagliflozin in the development of diabetic retinopathy
Biosci Rep. 2022 Mar 31;42(3):BSR20212209. doi: 10.1042/BSR20212209.ABSTRACTDiabetes mellitus is a chronic metabolic disease that occurs when the pancreas is not producing enough insulin or when the insulin that it does produce is not able to be used effectively in the body. This results in hyperglycemia and if the blood sugars are not controlled, then it can lead to serious damage of various body systems, especially the nerves and the blood vessels. Uncontrolled diabetes is a major cause of kidney failure, heart attacks, stroke and amputation. One of the most devastating complications for patients is diabetic retinopathy ...
Source: Bioscience Reports - March 2, 2022 Category: Biomedical Science Authors: Jennifer Matthews Lakshini Herat Jennifer Rooney Elizabeth Rakoczy Markus Schlaich Vance B Matthews Source Type: research
Beneficial cardiovascular and remodeling effects of SGLT2 inhibitors: pathophysiologic mechanisms
Expert Rev Cardiovasc Ther. 2022 Mar 23. doi: 10.1080/14779072.2022.2057949. Online ahead of print.ABSTRACTINTRODUCTION: The intent of this paper is to review the data regarding the multipotential effects of the sodium-glucose cotransporter 2 (SGLT 2) inhibitors, their cardiovascular protective effects, and their mechanism of action.AREAS COVERED: The SGLT2 inhibitors exert their beneficial antidiabetic and cardioprotective effects through increased glucose excretion from the kidneys, blood pressure and weight lowering, vasodilation and other potential beneficial effects. They have been used for the treatment of patients w...
Source: Expert Review of Cardiovascular Therapy - March 23, 2022 Category: Cardiology Authors: Steven G Chrysant George S Chrysant Source Type: research
Letter to the Editor Regarding “The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus”
Source: Cardiovascular Drugs and Therapy - May 11, 2022 Category: Cardiology Source Type: research
Response to the Letter on “The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus”
Source: Cardiovascular Drugs and Therapy - May 19, 2022 Category: Cardiology Source Type: research
Letter to the Editor Regarding “The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus”
Source: Cardiovascular Drugs and Therapy - May 19, 2022 Category: Cardiology Source Type: research
Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors
Med (N Y). 2021 Nov 12;2(11):1203-1230. doi: 10.1016/j.medj.2021.10.004.ABSTRACTCardiovascular and renal outcome trials (CVOTs) for glucagon-like-peptide-1 receptor agonists (GLP1RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) highlight new options for people with and without type 2 diabetes (T2D). Drugs within these classes reduce rates of major adverse cardiovascular events (MACE), with SGLT2i simultaneously attenuating decline in kidney function. SGLT2i reduce rates of heart failure in people with and without T2D, whereas GLP1RA lower rates of myocardial infarction and stroke in people with T2D with or withou...
Source: Atherosclerosis - May 19, 2022 Category: Cardiology Authors: David Z I Cherney Jacob A Udell Daniel J Drucker Source Type: research
SGLT2 Inhibitors a Better First Drug in Type 2 Diabetes Than Metformin?
(MedPage Today) -- Using SGLT2 inhibitors in the first-line treatment of type 2 diabetes lowered some cardiovascular risk, a claims database study showed.
The combined 12-month risk for myocardial infarction (MI), stroke, and death was similar...
Source: MedPage Today Cardiovascular - May 23, 2022 Category: Cardiology Source Type: news
Treatment of diabetes mellitus has borne much fruit in the prevention of cardiovascular disease
ABSTRACTCardiovascular (CV) disease is the most alarming complication of diabetes mellitus (DM), and a strategy aiming at CV event prevention in DM has long been debated. Large landmark clinical trials have shown CV benefits of intensive glycemic control as a “legacy effect” in newly diagnosed type 2 DM (T2DM). In contrast, we have learned that excessive intervention aimed at strong glycemic control could cause unexpected CV death in patients who are resistant to treatments against hyperglycemia. It has also been shown that the comprehensive multifac torial intervention for CV risk factors that was advocated in the cur...
Source: Journal of Diabetes Investigation - May 31, 2022 Category: Endocrinology Authors: Hiroaki Yagyu,
Hitoshi Shimano Tags: REVIEW ARTICLE Source Type: research
